The Journal of Pediatric Nursing has retracted a 2013 article (meeting abstract, really) on growth hormone after the drug company that employed the authors cried “take it back.”
The research appears to have been presented at a meeting of the Pediatric Endocrinology Nursing Society, and looked at inefficiency in the use of devices for administering growth hormone. All but one of the authors is listed as working for Novo Nordisk, an international pharmaceutical firm.
Ariel Fernandez, an Argentine chemist (who claims to hold the fastest-awarded PhD from Yale) and the subject of institutional investigations at multiple universities, has corrected several papers recently. What makes the moves particularly unusual — and interesting — is the stated reason for the amendments: disclaiming any funding from the National Institutes of Health for the work.
Fernandez was the recipient in 2005 of a $275,880 award “Protein packing defects as functional markers and drug targets.” The following year he received $294,217, and in 2007, $284,461, for the same four-year project, if we’re reading the link correctly.
On Wednesday, we brought you the story of a retraction by Gerold Feuer, a State University of New York (SUNY) Upstate Medical Center stem cell scientist whom the university had found to have misused grants. He was suspended, but successfully fought that action. We had asked Feuer for comment at that time, and he has now responded:
SUNY Upstate Medical University’s decision to widely publicize the recent decision by the journal Stem Cells to retract an article from my laboratory is a vindictive and retaliatory campaign to defame my scientific credentials in the press and to my scientific colleagues.
I unequivocally state that the data in all published manuscripts is valid and sound and is not falsified or fabricated. SUNY UMU unilaterally requested a retraction from Stem Cells, despite the fact that the federal Office of Research Integrity (ORI) has not yet ruled on these allegations. It is not surprising that UMU has decided to publicize this retraction in a public forum as a second attempt to force me from my tenured faculty position and circumvent decision of the employment arbitrator and the New York Supreme Court.
A group of authors from Saudi Arabia and Egypt has lost their 2012 paper in the International Journal of Dentistry for what appears to be a case of large-scale lifting of text from a previously published paper.
Stem Cells and Development has retracted a paper it published earlier this year after the leader of the study reported that the data were unreliable.
The paper, “Derivation and Genetic Modification of Embryonic Stem Cells from Disease-Model Inbred Rat Strains,” came from the lab of Aron Geurts, of the Medical College of Wisconsin.
A stem cell journal is retracting a paper by Gerold Feuer, a researcher at the State University of New York (SUNY) Upstate Medical Center in Syracuse who was also found to have misused grants.
The Feuer story is complicated. Heralded in 2008 for landing $6.2 million in grants from the New York Stem Cell Board, Feuer was suspended in October 2010 while the university investigated allegations he had misused funds, specifically to funnel state dollars to HuMurine, a company he founded in 2008. In December 2010, Upstate said they had found evidence he had committed 53 acts of financial misconduct, and dismissed him.
The Journal of Pediatric Nursing has retracted a 2013 article (meeting abstract, really) on growth hormone after the drug company that employed the authors cried “take it back.”
